Journal of Oncology Pharmacy Practice最新文献_第5页

Pharmacotherapy and psychological support: Integrating pharmacists into comprehensive cancer care - a literature review. 药物治疗和心理支持：将药剂师纳入综合癌症治疗-文献综述。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-07-01 Epub Date: 2025-02-03 DOI: 10.1177/10781552251316827

Haneen Badreldin Ali, Ujunwa P Dike, Muhammad Burhan Khan, Naiba Khusrau

{"title":"Pharmacotherapy and psychological support: Integrating pharmacists into comprehensive cancer care - a literature review.","authors":"Haneen Badreldin Ali, Ujunwa P Dike, Muhammad Burhan Khan, Naiba Khusrau","doi":"10.1177/10781552251316827","DOIUrl":"10.1177/10781552251316827","url":null,"abstract":"Cancer presents significant physical and mental challenges to patients. Therefore, psychological assessment is important following a cancer diagnosis, as well as during and after chemotherapy. In cancer treatment, the goal of healthcare providers, including pharmacists, should be to deliver holistic care that addresses important aspects of patients' health, with particular emphasis on their psychological readiness to combat their diseases. This article reviews published literature from Google Scholar and PubMed to examine the relevant pharmacotherapy and psychotherapy approaches to managing psychological issues in cancer patients. This article also discusses how pharmacists can be integrated into cancer patients' mental health care, while highlighting the potential benefits and challenges associated with this approach. We conclude that the integration of pharmacists into psychological care and support for cancer patients holds promise due to their knowledge of cancer chemotherapy, their ability to improve their knowledge about psychological care, and their capacity to collaborate with other healthcare professionals in cancer treatment.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"818-826"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of BRCA 1 mutated breast cancer with a PARP inhibitor and an Immune Checkpoint Inhibitor. PARP抑制剂和免疫检查点抑制剂治疗brca1突变乳腺癌

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-07-01 Epub Date: 2025-02-17 DOI: 10.1177/10781552251320049

Christina Hoppe, Kiera Roubal, Sushma Pavuluri, Oleksandra Lupak

{"title":"Treatment of BRCA 1 mutated breast cancer with a PARP inhibitor and an Immune Checkpoint Inhibitor.","authors":"Christina Hoppe, Kiera Roubal, Sushma Pavuluri, Oleksandra Lupak","doi":"10.1177/10781552251320049","DOIUrl":"10.1177/10781552251320049","url":null,"abstract":"IntroductionTriple negative breast cancer (TNBC) has traditionally been challenging to treat due to its lack of hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2), which were perceived as the only \"targets\" for treatment of breast cancer. Since 2017, targeted treatment options, such as olaparib, have been approved for the treatment of germline BReast CAncer gene (BRCA) mutated breast cancer, and immune checkpoint inhibitors for TNBC.Case ReportA 45-year-old female was diagnosed with BRCA1 mutated TNBC and ovarian cancer in 2018, and adjuvant treatment was partially completed. In 2020, her CA-125 rose and olaparib was initiated. Due to tolerability, she stopped treatment and transitioned to surveillance. In 2021, imaging showed brain metastases, and she started capecitabine. In November 2021 she progressed and transferred care to us.Management and OutcomeDue to suspected dual metastatic TNBC and ovarian cancers, and ovarian tissue demonstrating a combined positive score (CPS) of 3, gemcitabine, carboplatin and pembrolizumab were initiated. After six cycles, imaging demonstrated resolution of brain lesions, and pembrolizumab maintenance was continued. In March 2023, she switched to carboplatin, paclitaxel and bevacizumab, due to suspected progression of her ovarian cancer and resolution of breast cancer. She continued until December 2023 and switched to olaparib and bevacizumab.DiscussionThere is limited data to support sequential use of immunotherapy following treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor. The case report presented here demonstrates successful treatment of a patient with BRCA1 mutated TNBC treated with pembrolizumab after olaparib.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"850-852"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Proton pump inhibitors decrease efficacy of palbociclib in patients with metastatic breast. 质子泵抑制剂会降低帕博西尼对转移性乳腺癌患者的疗效

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-07-01 Epub Date: 2024-08-02 DOI: 10.1177/10781552241269677

Javier Álvarez Criado, Pilar Zamora Auñon, Virginia Martínez Marín, Macarena GarcíaTrevijano Cabetas, Victoria Lucía Collada Sánchez, Enrique Espinosa Arranz, José Antonio Romero-Garrido, Juana Benedi-González, Mariana Díaz Almirón, Alicia Herrero Ambrosio

{"title":"Proton pump inhibitors decrease efficacy of palbociclib in patients with metastatic breast.","authors":"Javier Álvarez Criado, Pilar Zamora Auñon, Virginia Martínez Marín, Macarena GarcíaTrevijano Cabetas, Victoria Lucía Collada Sánchez, Enrique Espinosa Arranz, José Antonio Romero-Garrido, Juana Benedi-González, Mariana Díaz Almirón, Alicia Herrero Ambrosio","doi":"10.1177/10781552241269677","DOIUrl":"10.1177/10781552241269677","url":null,"abstract":"ObjectivesThe objective of this investigation was to assess the impact of concurrent proton pump inhibitors (PPIs) on progression-free survival (PFS) in patients with hormone receptor-positive and HER2-negative metastatic breast cancer (mBC) who received palbociclib as first-line or successives therapy.Materials and MethodsA retrospective observational study was conducted, enrolling patients diagnosed with estrogen receptor-positive, human epidermal growth factor receptor 2-negative mBC, and eligible for palbociclib treatment. Patients were categorized as \"concurrent PPIs\" if they received PPIs for at least two-thirds of the palbociclib therapy duration, and as \"no concurrent PPIs\" if they did not receive PPIs during the course of palbociclib treatment.ResultsA total of 165 patients were included in the study. Among first-line patients treated with palbociclib, those using concurrent PPIs exhibited a PFS of 8.88 months, while patients using palbociclib without concurrent PPIs had a PFS of 67.81 months (p < 0.0001). In second-line or subsequent treatments, patients on palbociclib with concurrent PPIs had a PFS of 7.46 months, whereas those using palbociclib without concurrent PPIs had a PFS of 17.29 months (p = 0.122).ConclusionThis study demonstrates that the concurrent use of PPIs in mBC patients receiving palbociclib negatively affects PFS, particularly in the first-line setting. Nevertheless, further investigation is warranted to explore the impact of PPIs on cycle-dependent kinase 4/6 inhibitors.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"795-802"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141878918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Knowledge mapping and visualization of trends of drug holiday in different solid tumours: A literature review. 不同实体肿瘤药物假期趋势的知识图谱和可视化：文献综述。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-07-01 DOI: 10.1177/10781552251355434

Romina Giannini, Andrealuna Ucciero, Alessia Romagnoli, Felice Musicco, Fiorenzo Santoleri, Paolo Abrate, Valentina Isgrò, Alberto Costantini, Ruggero Lasala

{"title":"Knowledge mapping and visualization of trends of drug holiday in different solid tumours: A literature review.","authors":"Romina Giannini, Andrealuna Ucciero, Alessia Romagnoli, Felice Musicco, Fiorenzo Santoleri, Paolo Abrate, Valentina Isgrò, Alberto Costantini, Ruggero Lasala","doi":"10.1177/10781552251355434","DOIUrl":"https://doi.org/10.1177/10781552251355434","url":null,"abstract":"ObjectiveThe evolution of chemotherapy regimens and biologic therapies has improved survival rates for cancer patients, requiring the management of increasingly complex treatment protocols. In this context, strategies such as drug holidays (DH), intermittent therapy, and maintenance approaches have been explored to reduce therapeutic burden and mitigate long-term toxicity. However, the use of DH in oncology remains poorly defined, with no standardized protocols or clear guidelines. This review aims to evaluate the application of DH in solid tumor treatments, focusing on its definition and correlation with clinical outcomes, particularly in reducing toxicity and delaying resistance.Data sourceSystematic search of the PubMed database was conducted, with the final search executed on June 30, 2024, to identify relevant studies on DH in cancer therapy.Data SummaryA systematic search of PubMed identified 27 relevant studies. DH was most frequently explored in colorectal cancer, with positive outcomes reported in prostate cancer, basal cell carcinoma, and thyroid cancer. However, negative outcomes were observed in renal cancer and melanoma. Definitions of DH varied widely between studies, complicating comparisons. While DH may reduce toxicity in specific cancers, such as prostate and thyroid cancers, its clinical efficacy and long-term benefits remain unclear.ConclusionNo study has shown robust evidence supporting DH as a universally beneficial strategy. Further well-designed studies are needed to clarify its role in cancer treatment.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251355434"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Outcome of antiemetic prophylaxis among pediatric cancer patients receiving moderate to highly emetogenic chemotherapy at pediatric hemato-oncology ward of Tikur Anbessa specialized hospital: A prospective observational study. Tikur Anbessa 专科医院儿科血液肿瘤病房接受中度至高度致吐化疗的儿科癌症患者的止吐预防结果：前瞻性观察研究。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-07-01 Epub Date: 2024-05-21 DOI: 10.1177/10781552241256091

Hawaryaw Mathewos Hadero, Melak Gedamu Beyene, Assefa Mulu Baye, Eskinder Ayalew Sisay

{"title":"Outcome of antiemetic prophylaxis among pediatric cancer patients receiving moderate to highly emetogenic chemotherapy at pediatric hemato-oncology ward of Tikur Anbessa specialized hospital: A prospective observational study.","authors":"Hawaryaw Mathewos Hadero, Melak Gedamu Beyene, Assefa Mulu Baye, Eskinder Ayalew Sisay","doi":"10.1177/10781552241256091","DOIUrl":"10.1177/10781552241256091","url":null,"abstract":"IntroductionChemotherapy-induced nausea and vomiting (CINV) is a major issue for chemotherapy pediatric patients, especially in developing countries due to limited access to essential antiemetics. This study aimed to assess antiemetic prophylaxis outcomes in pediatric cancer patients at Tikur Anbessa Specialized Hospital in Addis Ababa, Ethiopia.MethodsA longitudinal prospective observational study design was conducted among 201 pediatric cancer patients followed up to 120 h post-chemotherapy.ResultsThe majority of patients (75.1%) received combination prophylactic antiemetics in the acute phase. Complete response (CR) was the highest in the acute phase (71.1%). Emesis episodes occurred most frequently on the first day of treatment (28.4%) and gradually decreased over time. History of motion sickness, platinum-based chemotherapy, and prior chemotherapy-induced vomiting (CIV) were associated with emesis during the acute phase whereas multiple-day chemotherapy, prior CIV, receipt of antiemetics, and a history of motion sickness in the delayed phase. However, the odds of CIV were reduced with steroid presence in the chemotherapy regimen.ConclusionsA considerable number of participants could not achieve a CR. It is important for clinicians to be cognizant of risk factors that influence the outcome of antiemetic prophylaxis to achieve better control of CINV among pediatric cancer patients.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"709-719"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141076187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating the efficacy of a premedication regimen including high-dose cetirizine in reduction of hypersensitivity reactions to paclitaxel: A retrospective cohort study. 评估包括大剂量西替利嗪在内的预处理方案对减少紫杉醇超敏反应的疗效：一项回顾性队列研究。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-07-01 Epub Date: 2024-07-23 DOI: 10.1177/10781552241263832

Alexander Hutchinson, Kelly Weaver, Bakeerathan Gunaratnam, Lesley Volz, Lauren Ingles, Lindsay Figg

{"title":"Evaluating the efficacy of a premedication regimen including high-dose cetirizine in reduction of hypersensitivity reactions to paclitaxel: A retrospective cohort study.","authors":"Alexander Hutchinson, Kelly Weaver, Bakeerathan Gunaratnam, Lesley Volz, Lauren Ingles, Lindsay Figg","doi":"10.1177/10781552241263832","DOIUrl":"10.1177/10781552241263832","url":null,"abstract":"IntroductionHypersensitivity reactions (HSR) are a known adverse effect of paclitaxel, occurring in approximately 10% of patients, typically during the first or second infusion of the medication. Corticosteroids, histamine-1 and histamine-2 receptor antagonists are given prior to paclitaxel infusions to reduce the incidence of HSR. There are limited data that suggest administration of cetirizine given prior to a platinum infusion as secondary prophylaxis may reduce HSR rates.MethodsThe objective of this study was to assess the impact of a novel paclitaxel hypersensitivity prevention protocol including high-dose cetirizine administered 12 and 6 h prior to paclitaxel infusion on the rate of HSR compared to a historical control. The primary objective was the rate of HSR of any grade after the first cycle of paclitaxel. Secondary outcomes included grade of infusion reaction and incidence of severe HSR.ResultsA total of 104 patients were included for analysis in the cetirizine group and 124 in the control group. Hypersensitivity reactions occurred in 37 (16.2%) patients in the overall population, and no statistical difference was observed between groups. (13.46% vs 18.55%; p = 0.23). Numerically more grade 3-4 HSRs occurred in the control group than the treatment group (30.77% vs 69.23; p = 0.51).ConclusionsThe addition of cetirizine to paclitaxel infusions resulted in numerically lower rates of HSR and a reduction in severity of grade 3-4 HSRs. Future studies with more robust compliance data and a larger patient population would be needed to appropriately assess the efficacy of our novel treatment regimen.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"810-817"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141752017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of a pharmacist-led oral chemotherapy monitoring clinic at the South Texas Veterans Health Care System. 南德克萨斯退伍军人医疗保健系统药剂师主导的口服化疗监测诊所的影响。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-07-01 Epub Date: 2024-05-21 DOI: 10.1177/10781552241256034

Cheyanne Shook, John Malamakal, Michael J Gass, Audrey Brown, Christopher R Frei, Amy Horowitz

{"title":"Impact of a pharmacist-led oral chemotherapy monitoring clinic at the South Texas Veterans Health Care System.","authors":"Cheyanne Shook, John Malamakal, Michael J Gass, Audrey Brown, Christopher R Frei, Amy Horowitz","doi":"10.1177/10781552241256034","DOIUrl":"10.1177/10781552241256034","url":null,"abstract":"As cancer treatments shift from traditional intravenous chemotherapy to inclusion of oral oncolytics, there is a critical need for structured oral chemotherapy monitoring and follow-up programs. To provide continuous care and minimize clinical gaps to Veterans receiving oral chemotherapy, the hematology/oncology clinical pharmacy practitioners designed and initiated a pilot, pharmacist-driven, Oral Chemotherapy Monitoring Clinic at the South Texas Veterans Health Care System supported by an oral chemotherapy certified pharmacy technician. A retrospective evaluation of patients receiving oral chemotherapy at the South Texas Veterans Health Care System was performed before (Phase I) and after (Phase II) pilot implementation to assess the impact of an Oral Chemotherapy Monitoring Clinic on compliance with drug-specific lab and symptom monitoring. Complete monitoring was defined as 100% of recommended labs and symptoms assessed per cycle, partial monitoring was <100%, but >0%, and incomplete monitoring was defined as 0%. The primary outcome assessed the proportion of patients receiving complete monitoring in Phase II compared to Phase I. Most patients were male (94%), with a median age of 72 years. The most common oncolytic was abiraterone acetate. Overall, drug-specific baseline and follow-up laboratory and symptom monitoring was complete at a statistically significantly higher rate in Phase II compared with Phase I (p-value < 0.01). A significantly higher portion of patients in the Phase II cohort had a clinical pharmacy practitioner intervention (44% vs. 90%; p < 0.01). Monitoring for Veterans receiving oral chemotherapy was optimized with clinical pharmacy practitioner and certified pharmacy technician involvement while simultaneously alleviating Oncologist and nurse oral chemotherapy workload.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"700-708"},"PeriodicalIF":1.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141076186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lactose intolerance or gastrointestinal adverse drug effect? guidance for oncology pharmacists. 乳糖不耐症还是胃肠道药物不良反应？肿瘤学药师指南。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-06-27 DOI: 10.1177/10781552251352203

Lisa Wanbon, Nadine Badry, Mário L de Lemos

{"title":"Lactose intolerance or gastrointestinal adverse drug effect? guidance for oncology pharmacists.","authors":"Lisa Wanbon, Nadine Badry, Mário L de Lemos","doi":"10.1177/10781552251352203","DOIUrl":"https://doi.org/10.1177/10781552251352203","url":null,"abstract":"Lactose intolerance is quite common among people world-wide. Despite this, lactose is often used as a pharmaceutical excipient due to its pharmacologically inactive nature. We reviewed the literature to determine how much lactose can typically be tolerated by patients reporting a history of lactose intolerance and measured the amount of excipient in commonly used solid oral oncology dosage forms. We determined that most patients should be able to tolerate a significantly higher amount of lactose than that found in maximum daily doses of oncology tablets and capsules, based on our literature review and the measured amount of excipient in commonly used solid oral oncology dosage forms. If patients report gastrointestinal symptoms, adverse drug reactions and medical conditions should be considered as more likely causes than lactose intolerance. We created a flow chart for pharmacists to follow when dispensing oral medications to lactose intolerant patients. This chart may assist in patient management if the lactose content of a medication is questioned or if a patient reports gastrointestinal symptoms.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251352203"},"PeriodicalIF":1.0,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144506018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Implementation of a pharmaceutical care model within paediatric oncology. 儿科肿瘤药物治疗模式的实施。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-06-26 DOI: 10.1177/10781552251350553

Sephorah Falzon, Nathalie Galea, Jennifer T Pham, Louise Grech, Lilian M Azzopardi

{"title":"Implementation of a pharmaceutical care model within paediatric oncology.","authors":"Sephorah Falzon, Nathalie Galea, Jennifer T Pham, Louise Grech, Lilian M Azzopardi","doi":"10.1177/10781552251350553","DOIUrl":"https://doi.org/10.1177/10781552251350553","url":null,"abstract":"IntroductionDue to the complex needs, paediatric oncology patients require specialized pharmaceutical care provided within an interdisciplinary setting.ObjectiveTo implement a Pharmaceutical Care Model at the Paediatric-Adolescent Oncology Unit (PAOU) at Sir Anthony Mamo Oncology Centre, Malta, focusing on individualised pharmaceutical care issues (PCIs) based on patient specific needs.MethodsA tool consisting of a novel PCI classification system based on the Pharmaceutical Care Network Europe Foundation classification for drug related problems and the DOCUMENT system was developed to document and classify PCIs. The tool was presented in tabular format with eleven PCI categories, category description, PCIs, pharmaceutical interventions, and outcomes. Following ethics approval, the pharmacist attended consultant-led ward rounds where patient files, treatment charts and chemotherapy prescriptions were reviewed to identify PCIs. Identified PCIs were discussed with the healthcare team, pharmaceutical interventions were proposed, and outcomes were recorded.ResultsValidation and practicality testing demonstrated tool relevance, robustness, and practicality for use at the PAOU. Over 8 months, 545 PCIs were identified during 325 pharmaceutical care sessions. Most PCIs featured in the counselling (26.97%), drug selection (23.67%), dose selection (19.27%) and monitoring (15.41%) categories. The majority (95% n = 516) of the proposed pharmaceutical interventions were accepted and implemented by the healthcare professionals or the parents.ConclusionThis study highlights the pharmacist's contribution to paediatric oncology care through a pharmaceutical care model focused on PCIs and patient specific needs. The high acceptance rate of pharmaceutical interventions demonstrates the model's quality, the clinical pharmacist's professional competence, effective interdisciplinary collaboration, and integration within the healthcare team.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251350553"},"PeriodicalIF":1.0,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144497366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhancing oncology care: A prospective observational study on counseling practices of hospital pharmacists. 加强肿瘤护理：医院药师咨询实践的前瞻性观察研究。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-06-26 DOI: 10.1177/10781552251351325

S A M Urru, S Masucci, P Baldo, U Gallo, P Schincariol, P Silimbani, S Vecchia, V Damuzzo

{"title":"Enhancing oncology care: A prospective observational study on counseling practices of hospital pharmacists.","authors":"S A M Urru, S Masucci, P Baldo, U Gallo, P Schincariol, P Silimbani, S Vecchia, V Damuzzo","doi":"10.1177/10781552251351325","DOIUrl":"https://doi.org/10.1177/10781552251351325","url":null,"abstract":"IntroductionPharmacists are crucial in oncology and haematology, especially in medication management, patient counselling, and healthcare team collaboration. Their roles differ across institutions and countries. In Italy, where hospital pharmacies distribute oral cancer therapies, there is an emerging need for standardized counselling practices to enhance patient outcomes. This study aims to examine the current counselling practices of hospital pharmacists in Italy's oncology and haematology settings, identifying areas for improvement to better support patient care.MethodA web-based questionnaire was used for this prospective observational study, distributed through a national oncology pharmacists' network (Oncofarma). It was organized into three sections covering demographic information, counselling activities for patients and physicians, and communication methods. Data were analysed descriptively, with participants recruited through convenience sampling.ResultsOf the 99 participants from 61 centres surveyed, most were NHS hospital pharmacists. Half provided advice to oncologists or haematologists, and 36% engaged in direct patient counselling. Pharmacists typically advised on drug administration, side effects, and drug interactions, with communication primarily through face-to-face interactions or telephone calls. Counselling often took place at pharmacy counters or on hospital wards, with limited access to dedicated consultation spaces or times.ConclusionThe study reveals variability in Italian hospital pharmacists' counselling practices in oncology and haematology. Expanding patient counselling and introducing structured communication protocols may improve care quality. Standardised guidelines and training in communication, clinical knowledge and documentation could improve consistency, improve patient outcomes and support the integration of pharmacists into the healthcare team.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251351325"},"PeriodicalIF":1.0,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144497365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0